cafepharmaNov 21, 2023
Merck drops up to $610M on neuro disease-focused Caraway Therapeutics -- AstraZeneca’s Imfinzi Phase III trial raises trial design questions --Teva granted pretrial appeal in high-stakes Copaxone kickbacks case-- See more on our front page news http://bit.ly/w28kSd #merck #mergersandacquisitions #astrazeneca #imfinzi #clinicaltrials #tevapharm #copaxone #kickbacks #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Cafepharma

Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.

Cafepharma
Your Autistic Life Sep 6, 2023

Wow... three years after doctors misdiagnosed me with multiple sclerosis, I get a letter from Teva Neuroscience telling me that they can't provide some copaxone syringe anymore.

I feel so taken care of!

Turns out I had cancer. The joke's on them!  

#doctors #misdiagnosis #MultipleSclerosis #TevaNeuroscience #copaxone #syringe #cancer

Gothsong 💀📚☕Nov 19, 2022
@sburall I am in Canada so names may be different. #Copaxone is great for many people, but there are lot of new ones out there like #Ocrevus (an infusion) and #Aubagio (a daily pill). My MS has been very slow progressing so I am on Aubagio it's "less aggressive" but I have heard amazing things about Ocrevus for those with a less manageable disease.